Country: Malta
Language: English
Source: Medicines Authority
HEPARIN SODIUM
Wockhardt UK Limited
B01AB
HEPARIN SODIUM
SOLUTION FOR INFUSION OR INJECTION
HEPARIN SODIUM 1000 IU/ml
POM
ANTITHROMBOTIC AGENTS
Authorised
2006-08-23
PACKAGE LEAFLET: INFORMATION FOR THE USER HEPARIN SODIUM 1,000 I.U./ML SOLUTION FOR INJECTION OR CONCENTRATE FOR SOLUTION FOR INFUSION PRESERVATIVE FREE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, please ask your doctor or nurse. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. The name of your medicine is heparin sodium 1,000 I.U./ml solution for injection or concentrate for solution for infusion. In the rest of this leaflet it is called heparin injection. IN THIS LEAFLET: 1. What heparin injection is and what it is used for 2. Before you are given heparin injection 3. How heparin injection is given 4. Possible side effects 5. How to store heparin injection 6. Further information 1. WHAT HEPARIN INJECTION IS AND WHAT IT IS USED FOR Heparin belongs to a group of drugs that are called anti-coagulants. These help to stop blood clotting. Heparin injection is used in conditions where blood vessels may become blocked by blood clots. It is therefore used to treat: • blood clots in leg veins (deep vein thrombosis) • blood clots in the lung (pulmonary embolism) as well as for: • the treatment of chest pains resulting from disease of the heart arteries (unstable angina pectoris) • the treatment of severe blockages affecting arteries in the legs (acute peripheral arterial occlusion) It is also used during heart and lung operations and during kidney dialysis. 2. BEFORE YOU ARE GIVEN HEPARIN INJECTION HEPARIN INJECTION SHOULD NOT BE GIVEN IF YOU: • are allergic to heparin or any of the other ingredients in your medicine, (see ‘What heparin injection contains’ section 6) • drink large amounts of alcohol • are currently bleeding from anywhere in the body, (apart from your normal periods which does not stop you being given heparin injection) • have haemophilia (a genetic disorder which may cause you to b Read the complete document
Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Monoparin 1,000 I.U./ml Solution for injection or concentrate for solution for infusion or Heparin sodium 1,000 I.U./ml Solution for injection or concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSTION Heparin sodium 1,000 I.U./ml (1,000 I.U./ml in 1ml, 5,000 I.U. in 5ml, 10,000 I.U in 10ml and 20,000 I.U in 20ml) For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for injection or concentrate for solution for infusion A colourless or straw-coloured liquid, free from turbidity and from matter that deposits on standing. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of deep vein thrombosis, pulmonary embolism, unstable angina pectoris and acute peripheral arterial occlusion. In extracorporeal circulation and haemodialysis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ _ _Route of administration_ By continuous intravenous infusion in 5% glucose or 0.9% sodium chloride or by intermittent intravenous injection. As the effects of heparin are short-lived, administration by intravenous infusion is preferable to intermittent intravenous injections. _ _ _Recommended dosage _ Treatment of deep vein thrombosis, pulmonary embolism, unstable angina pectoris, acute peripheral arterial occlusion: Page 2 of 8 _ _ _Adults:_ Loading dose: 5,000 units intravenously (10,000 units may be required in severe pulmonary embolism) Maintenance: 1,000-2,000 units/hour by intravenous infusion, or 5,000-10,000 units 4-hourly by intravenous injection. _Elderly:_ Dosage reduction may be advisable. _ _ _Children and small adults:_ Loading dose: 50 units/kg intravenously Maintenance: 15-25 units/kg/hour by intravenous infusion, or 100 units/kg 4-hourly by intravenous injection Daily laboratory monitoring (ideally at the same time each day, starting 4-6 hours after initiation of treatment) is essential during full-dose heparin treatment, with adjustment of dosage to maintain an APTT value 1.5-2.5 x midpoint o Read the complete document